Loading
Integra Lifesciences Holdings Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 06 Nov 2025.
Integra Lifesciences Holdings Corp: what insiders have been doing
Integra Lifesciences Holdings Corp, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 8 insiders have disclosed 11 filings since 18 October 2025.
Every open-market trade in the period is a purchase: 1 purchase worth €89k, from 1 insider, and not a single sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. One trade stands out by size: a purchase of €89k from Graves Jeffrey A, disclosed on 6 November 2025. On the buying side, the filings list 1 senior executive among the declarants.
For context, the typical company on the same exchange (median of 5,816 companies) published 19 filings over the same period, against 11 filings here. Since 2016, the database holds 5 purchases and 22 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 1.64 bn USD and net income of -516.5 m USD.
The most recent open-market purchase was published on 6 November 2025, 346 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
167
Thresholds
n/a
Buy Volume
€3M
5 ops. · all time
Sell Volume
€23M
22 ops. · all time
Who traded when
BuySaleEric Schwartz1 sale
Jeffrey A. Graves1 buy
Michael J. McBreen1 sale
Since the insiders bought
- -9.6%Entry US$12.04 · Close at T+90 US$10.88
- -54.6%Entry US$28.87 · Close at T+365 US$13.12
- -56.9%Entry US$28.51 · Close at T+365 US$12.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Integra Lifesciences Holdings Corp Hold (neutral), based on 9 analysts. Average price target: US$18.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,108 of 24,148 companies
24.8
score / 100
Value15
Quality35
FCF yld-4.3%
Earn yld-49%
EV/EBITDA·
ROE-0.7%
Gross mgn51%
Net mgn-32%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$13.53
Analyst consensus
9 analystsHold
US$14.00Target US$18.00(+33%)US$27.00
Income statement
RevenueUS$1.6B
Gross profitUS$831.6M51% margin
EBITDA-US$325.4M-20% margin
Net income-US$516.5M-0.4% margin
Valuation
PER (forward)5.3x
P/Book1.0x
Beta1.21
Balance sheet & cash
Market capUS$1.1B
Total debtUS$2B
Free Cash Flow-US$45.3M
Debt / Equity196%
Profitability & ownership
ROE-0.7%
ROA2.8%
% insiders14.4%
% institutions98.7%
Last declaration on 4 September 2026
Declarations167 total
1,455 shares@ US$16.620.0019% mcap15.9% of flowCommon StockSEC:0001990905-26-000004:0
5,226 shares@ US$18.050.0075% mcap29.0% of flowCommon StockSEC:0001983748-26-000003:0
937 shares@ US$17.890.0013% mcap6.3% of flowCommon StockSEC:0001719686-26-000003:0
5,420 shares@ US$9.6134.3% of flowCommon StockSEC:0001990905-26-000002:0
687 shares@ US$9.551.5% of flowCommon StockSEC:0001563606-26-000001:0
8,089 shares@ US$9.6123.6% of flowCommon StockSEC:0001983748-26-000001:0
2,354 shares@ US$9.552.1% of flowCommon StockSEC:0001814943-26-000001:0
341 shares@ US$9.551.2% of flowCommon StockSEC:0001719686-26-000001:0
1,216 shares0Common StockSEC:0001949782-26-000001:0
848 shares0Common StockSEC:0001743760-26-000002:0
9,000 shares@ US$11.35100.0% of flowCommon StockSEC:0001251036-25-000006:0
Canonical exit: 3 Feb 2026 (T+90)
11,965 shares0Common StockSEC:0001949782-25-000003:0
2,139 shares@ US$15.1321.1% of flowCommon StockSEC:0000917520-25-000083:0
200,000 shares@ US$13.6262.8% of flowCommon StockSEC:0000917520-25-000078:0
2,561 shares@ US$13.4910.4% of flowCommon StockSEC:0000917520-25-000063:0
3,345 shares@ US$13.4916.5% of flowCommon StockSEC:0000917520-25-000062:0
937 shares@ US$13.254.5% of flowCommon StockSEC:0000917520-25-000061:0
19,592 shares0Common StockSEC:0000917520-25-000045:0
6,939 shares0Common StockSEC:0000917520-25-000046:0
6,939 shares0Common StockSEC:0000917520-25-000044:0
19,592 shares0Common StockSEC:0000917520-25-000048:0
6,939 shares0Common StockSEC:0000917520-25-000043:0
19,592 shares0Common StockSEC:0000917520-25-000047:0
392 shares@ US$12.2589.0% of flowCommon StockSEC:0000917520-25-000049:0
1,655 shares@ US$23.9512.9% of flowCommon StockSEC:0000917520-25-000028:0
25 of 167 declarations
About Integra Lifesciences Holdings Corp
Integra LifeSciences Holdings Corp. (ticker: IART) is a U.S.-based medical technology company listed on the NASDAQ market in the United States, with headquarters in Princeton, New Jersey. Founded in 1989, the company was originally built around an engineered collagen technology platform designed to repair and regenerate tissue, and it has since broadened into a diversified medtech business serving surgical, neurologic, ENT (ear, nose and throat), and regenerative-care applications. Its customer base is primarily hospitals, surgeons, and specialty-care providers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/917520/000091752025000017/R9.htm?utm_source=openai))
Integra’s business model is centered on a portfolio of complementary products and solutions used across the operating room and adjacent clinical settings. The company markets devices and consumables for neurosurgery, general surgery, tissue reconstruction, wound care, and ENT procedures. This mix gives Integra exposure to multiple end markets while keeping its strategy focused on specialized, higher-value medical technologies rather than commoditized equipment. In practice, that means the company competes on clinical utility, surgeon relationships, product innovation, and regulatory execution, all of which are critical in the medical-device industry. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000917520/000091752025000017/iart-20241231.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Integra sits among specialized medtech suppliers rather than among the largest diversified healthcare conglomerates. Its differentiation lies in depth of indication-specific expertise, a broad surgical portfolio, and the ability to integrate acquisitions and manufacturing capabilities into its product platform. Recent disclosures show the company continuing to focus on portfolio optimization and operational improvements, including plans to relaunch SurgiMend and PriMatrix from a new state-of-the-art manufacturing facility in Braintree, Massachusetts, with operational readiness expected in the first half of 2026. ([sec.gov](https://www.sec.gov/Archives/edgar/data/917520/000091752024000092/ex991-q22024earningsrelease.htm?utm_source=openai))
Recent company updates also highlight ongoing execution efforts and commercial momentum. In its fourth-quarter and full-year 2024 results released in February 2025, Integra reported quarterly revenue growth and described early integration progress from the Acclarent ENT acquisition. For equity investors, the key analytical points are execution risk, manufacturing quality, product relaunch timing, and the company’s ability to translate its specialized portfolio into sustainable organic growth in the U.S. and international markets. As a NASDAQ-listed issuer in the United States, Integra remains a name to watch in the surgical and regenerative-medical device space. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000917520/000091752025000014/ex991q42024earnings.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
